Welcome to our dedicated page for Solana news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Solana stock.
Solana Company reports developments as a Nasdaq-listed company with a digital asset treasury dedicated to acquiring and holding Solana tokens (SOL) and a legacy neurotechnology medical-device business. News commonly covers SOL accumulation, staking rewards, NAV-per-share capital strategy, ATM and registered-direct equity financing, share repurchases, and financial results shaped by digital-asset fair value changes.
Company updates also describe institutional Solana infrastructure initiatives in Asia-Pacific, including validator and staking infrastructure, qualified-custody borrowing against natively staked SOL, and ecosystem partnerships with organizations such as Jito Foundation, Anchorage Digital, and Kamino.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Helius Medical Technologies (NASDAQ: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has announced its participation in the LD Micro Invitational XIII 2023. The event will take place at the Luxe Sunset Boulevard Hotel in California.
President and CEO Dane Andreeff, along with CFO Jeff Mathiesen, will represent Helius at the conference. Their presentation is scheduled for Wednesday, June 7, 2023, at 4:00 PM PT. Interested parties can access the webcast through the provided link.
Investors and attendees wishing to arrange one-on-one meetings with Helius management are encouraged to contact LD Micro directly. This event provides an opportunity for Helius to showcase its innovative approach to neuromodulation therapy and engage with potential investors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Helius Medical Technologies (NASDAQ: HSDT) will showcase its Portable Neuromodulation Stimulator (PoNS) device at the American Academy of Neurology (AAN) Annual Meeting for the first time since its launch in the U.S. and Canada. The device is authorized for use in managing gait deficits caused by multiple sclerosis, stroke, and mild-to-moderate traumatic brain injury. Helius reports promising clinical data, including over 55% average improvement in gait assessments among various patient groups. A notable finding includes 100% of MS participants improving their gait scores post-treatment. The AAN conference, held April 22-27, 2023, in Boston, allows for direct engagement with the medical team. This expansion of indications signals growing confidence in PoNS's efficacy and therapeutic potential.